Multiplier vs ArkeaBio

Side-by-side comparison of AI visibility scores, market position, and capabilities

Multiplier

GrowthHuman Resources

Global Employment Platform

Multiplier enables companies to employ international talent across 150+ countries through an EOR model with integrated payroll, benefits, and compliance management.

About

Multiplier is a Singapore-headquartered global employment platform founded in 2020 that has raised over $60M to help companies hire international employees without setting up local entities. The company acts as Employer of Record across 150+ countries, managing employment contracts, benefits, payroll, and tax compliance for employees on behalf of client companies. Multiplier differentiates through its Asia-Pacific market expertise and competitive pricing, serving startups and growth-stage companies that want cost-effective access to global talent pools. The platform includes tools for onboarding, document management, equity grants, and benefits administration that provide a complete employee lifecycle management experience. Multiplier has built strong coverage in Southeast Asian markets where it has local entity presence and deep compliance expertise. The company targets the underserved mid-market between Employer of Record platforms built for enterprises and DIY global hiring approaches used by early-stage companies. As global distributed hiring has become mainstream, Multiplier competes in a crowded but growing market by offering competitive economics and strong Asia-Pacific regional depth.

Full profile

ArkeaBio

EmergingAgTech

Livestock Biotech (Methane Reduction)

$40M+ total raised including $26.5M Series A. 2026-27 cattle field trials underway. Backed by Breakthrough Energy Ventures. Only company with a cattle methane vaccine in active trials.

About

ArkeaBio is developing a vaccine that reduces methane emissions from cattle and sheep by targeting the methanogenic archaea (ancient microorganisms) that produce methane in ruminant digestive systems. The company has raised $40 million+ including a $26.5 million Series A, backed by Breakthrough Energy Ventures and Gates Foundation-aligned capital, and has active cattle field trials underway in 2026-2027 — making it the only company with a livestock methane vaccine at this stage of clinical development.

Full profile

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.